Study of Valproic Acid to Treat HIV Infected Adults

Stopped early · Phase 1

Conditions studied: HIV Infections

In brief

A histone deacetylase (HDAC) inhibitor is a class of drug that interferes with the function of HDAC, an enzyme that hides HIV within inactive CD4 cells. These drugs are normally used to treat seizures and other nervous system problems but have been found to work against HIV. The purpose of this study is to investigate the efficacy of valproic acid (VPA), an HDAC inhibitor, in treating HIV infected adults using anti-HIV drugs.

Key facts

Study ID

NCT00312546

Run by

University of North Carolina, Chapel Hill

People needed

14

Starts

2006-06-01

Expected to finish

2009-10-01

Last updated by the study team

2012-05-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV-1 infected
• Adherent to current HAART regimen
• Adequate vascular access for leukapheresis
• Receiving HAART, defined as at least two nucleoside reverse transcriptase inhibitors plus at least one protease inhibitor or non-nucleoside reverse transcriptase inhibitor, without changes to the regimen within 24 weeks of study entry
• Viral load more than 50 copies/ml on two consecutive occasions for more than 6 months, and less than 200 copies/ml on occasion for more than 6 months prior to study entry
• CD4 count more than 300 cells/mm3
• Willing and able to comply with all study requirements
• Willing to use acceptable forms of contraception

You may not qualify if…

• Currently receiving zidovudine or enfuvirtide
• Require certain medications known to interact with valproate (e.g., lamotrigine; barbiturates; carbamazepine; prescription dosages of salicylates, hydantoins, felbamate, and clonazepam)
• Any medical, psychiatric, or job-related responsibility that would interfere with the study. More information about this criterion can be found in the protocol.
• Contraindications to taking VPA (e.g., pregnancy, bleeding disorders, history of pancreatitis, history of hepatitis)
• Receiving interferon, other immunomodulators, or other experimental medications
• Abnormal liver enzyme tests
• Hepatitis B virus infected
• Symptoms of hepatic decompensation
• Blood transfusions or hematopoietic growth factors within 90 days prior to study entry
• Systemic cytotoxic chemotherapy, investigational agents, or immunomodulators within 90 days prior to study entry
• Current drug or alcohol abuse that, in the opinion of the site investigator, would interfere with the study
• Serious illness requiring systemic treatment or hospitalization within 90 days prior to study entry
• Treatment for a current AIDS-defining opportunistic infection within 90 days prior to screening
• Anemic
• Involuntarily incarcerated for treatment of either a psychiatric illness or physical illness (e.g., infectious disease)
• Pregnancy or breastfeeding

Where it is running

• University of North Carolina Memorial Hospital — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.